Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.

ABSTRACT:

Background

A number of transporter proteins are expressed in the placenta, and they facilitate the placental transfer of drugs. The inhibition of P-glycoprotein (P-gp) was previously found to be associated with an increase in the risk of congenital anomalies caused by drug substrates of this transporter. We now explore the role of other placental transporter proteins.

Methods

A population-based case-referent study was performed using cases with congenital anomalies (N = 5,131) from EUROCAT Northern Netherlands, a registry of congenital anomalies. The referent population (N = 31,055) was selected from the pregnancy IADB.nl, a pharmacy prescription database.

Results

Ten placental transporters known to have comparable expression levels in the placenta to that of P-gp, we

SUBMITTER: Daud AN 

PROVIDER: S-EPMC5348032 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature